INmune Bio Inc
INMB1.830USD
+0.010+0.55%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
48.65MMarket Cap
LossP/E TTM
More Details of INmune Bio Inc Company
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.
INmune Bio Inc Info
Ticker SymbolINMB
Company nameINmune Bio Inc
IPO dateFeb 04, 2019
CEOMoss (David J)
Number of employees22
Security typeOrdinary Share
Fiscal year-endFeb 04
Address225 Ne Mizner Blvd, Suite 640
CityBOCA RATON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33432
Phone18589643720
Websitehttps://www.inmunebio.com/
Ticker SymbolINMB
IPO dateFeb 04, 2019
CEOMoss (David J)
Company Executives of INmune Bio Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Scott Juda, J.D.
Mr. Scott Juda, J.D.
Independent Director
Independent Director
71.60K
--
Mr. Cory Ellspermann
Mr. Cory Ellspermann
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Timothy (Tim) Schroeder
Mr. Timothy (Tim) Schroeder
Independent Director
Independent Director
--
--
Mr. David J. Moss
Mr. David J. Moss
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Prof. Mark Lowdell, Ph.D.
Prof. Mark Lowdell, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Marcia Allen
Ms. Marcia Allen
Independent Director
Independent Director
--
--
Mr. J. Kelly Ganjei
Mr. J. Kelly Ganjei
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Scott Juda, J.D.
Mr. Scott Juda, J.D.
Independent Director
Independent Director
71.60K
--
Mr. Cory Ellspermann
Mr. Cory Ellspermann
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Timothy (Tim) Schroeder
Mr. Timothy (Tim) Schroeder
Independent Director
Independent Director
--
--
Mr. David J. Moss
Mr. David J. Moss
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Prof. Mark Lowdell, Ph.D.
Prof. Mark Lowdell, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Marcia Allen
Ms. Marcia Allen
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Tesi (Raymond Joseph)
5.85%
Lowdell (Mark William)
5.68%
Moss (David J.)
4.84%
BlackRock Institutional Trust Company, N.A.
4.15%
The Vanguard Group, Inc.
3.30%
Other
76.19%
Shareholders
Shareholders
Proportion
Tesi (Raymond Joseph)
5.85%
Lowdell (Mark William)
5.68%
Moss (David J.)
4.84%
BlackRock Institutional Trust Company, N.A.
4.15%
The Vanguard Group, Inc.
3.30%
Other
76.19%
Shareholder Types
Shareholders
Proportion
Individual Investor
17.01%
Investment Advisor
11.81%
Investment Advisor/Hedge Fund
4.35%
Research Firm
0.96%
Venture Capital
0.18%
Hedge Fund
0.11%
Private Equity
0.09%
Bank and Trust
0.08%
Other
65.40%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
174
5.76M
21.67%
-1.34M
2025Q2
165
13.91M
52.32%
+314.04K
2025Q1
165
12.97M
59.27%
-484.99K
2024Q4
147
12.96M
58.46%
+804.75K
2024Q3
134
11.81M
53.27%
+318.25K
2024Q2
123
11.15M
54.62%
+1.47M
2024Q1
101
9.25M
51.52%
+199.50K
2023Q4
97
8.79M
48.95%
-237.73K
2023Q3
92
8.63M
48.03%
-362.72K
2023Q2
91
8.66M
48.24%
-1.19M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Tesi (Raymond Joseph)
1.55M
5.85%
--
--
Apr 14, 2025
Lowdell (Mark William)
1.51M
5.68%
--
--
Apr 14, 2025
Moss (David J.)
1.29M
4.84%
--
--
Apr 14, 2025
BlackRock Institutional Trust Company, N.A.
1.05M
3.94%
+170.94K
+19.52%
Jun 30, 2025
The Vanguard Group, Inc.
847.75K
3.19%
+21.14K
+2.56%
Jun 30, 2025
Geode Capital Management, L.L.C.
389.93K
1.47%
+25.07K
+6.87%
Jun 30, 2025
State Street Investment Management (US)
275.39K
1.04%
+39.26K
+16.63%
Jun 30, 2025
Raymond James Financial Services Advisors, Inc.
316.94K
1.19%
-62.04K
-16.37%
Jun 30, 2025
Northern Trust Investments, Inc.
162.46K
0.61%
+11.97K
+7.96%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
Avantis US Small Cap Equity ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Russell 2000 Growth ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0%
Fidelity Nasdaq Composite Index ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Global X Russell 2000 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of INmune Bio Inc?
The top five shareholders of INmune Bio Inc are:
Tesi (Raymond Joseph) holds 1.55M shares, accounting for 5.85% of the total shares.
Lowdell (Mark William) holds 1.51M shares, accounting for 5.68% of the total shares.
Moss (David J.) holds 1.29M shares, accounting for 4.84% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.05M shares, accounting for 3.94% of the total shares.
The Vanguard Group, Inc. holds 847.75K shares, accounting for 3.19% of the total shares.
Tesi (Raymond Joseph) holds 1.55M shares, accounting for 5.85% of the total shares.
Lowdell (Mark William) holds 1.51M shares, accounting for 5.68% of the total shares.
Moss (David J.) holds 1.29M shares, accounting for 4.84% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.05M shares, accounting for 3.94% of the total shares.
The Vanguard Group, Inc. holds 847.75K shares, accounting for 3.19% of the total shares.
What are the top three shareholder types of INmune Bio Inc?
The top three shareholder types of INmune Bio Inc are:
Tesi (Raymond Joseph)
Lowdell (Mark William)
Moss (David J.)
Tesi (Raymond Joseph)
Lowdell (Mark William)
Moss (David J.)
How many institutions hold shares of INmune Bio Inc (INMB)?
As of 2025Q3, 174 institutions hold shares of INmune Bio Inc, with a combined market value of approximately 5.76M, accounting for 21.67% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -30.65%.
What is the biggest source of revenue for INmune Bio Inc?
In --, the -- business generated the highest revenue for INmune Bio Inc, amounting to -- and accounting for --% of total revenue.
